(EXPO) Exponent - Ratings and Ratios
Engineering Consulting, Scientific Analysis, Regulatory Advice
EXPO EPS (Earnings per Share)
EXPO Revenue
Description: EXPO Exponent August 03, 2025
Exponent Inc (NASDAQ:EXPO) is a science and engineering consulting firm that provides a wide range of services across two main segments: Engineering and Other Scientific, and Environmental and Health. The companys expertise spans multiple areas, including biomechanics, data sciences, electrical engineering, and environmental sciences, among others.
The companys diverse service offerings enable it to cater to various industries, such as chemical, construction, consumer products, energy, and life sciences. Exponents clients include government agencies, insurance companies, manufacturers, and technology firms. With a history dating back to 1967, the company has established itself as a reputable player in the research and consulting services sector.
From a financial perspective, Exponents revenue growth and profitability are key performance indicators (KPIs) to monitor. The companys return on equity (RoE) of 25.33% indicates a strong ability to generate profits from shareholder equity. Additionally, the price-to-earnings (P/E) ratio of 34.85 and forward P/E of 36.50 suggest that investors have high expectations for the companys future earnings growth.
To further evaluate Exponents performance, other relevant KPIs could include revenue growth rate, operating margin, and employee utilization rates. The companys ability to attract and retain top talent in the science and engineering fields is also crucial to its success. Furthermore, Exponents competitive positioning within the research and consulting services industry, as well as its ability to adapt to changing regulatory environments, are important factors to consider when assessing its long-term prospects.
EXPO Stock Overview
| Market Cap in USD | 3,576m |
| Sub-Industry | Research & Consulting Services |
| IPO / Inception | 1990-08-17 |
EXPO Stock Ratings
| Growth Rating | -60.8% |
| Fundamental | 75.1% |
| Dividend Rating | 63.0% |
| Return 12m vs S&P 500 | -37.2% |
| Analyst Rating | 3.67 of 5 |
EXPO Dividends
| Dividend Yield 12m | 1.65% |
| Yield on Cost 5y | 1.67% |
| Annual Growth 5y | 10.18% |
| Payout Consistency | 100.0% |
| Payout Ratio | 58.4% |
EXPO Growth Ratios
| Growth Correlation 3m | -53.1% |
| Growth Correlation 12m | -97.2% |
| Growth Correlation 5y | -34.5% |
| CAGR 5y | -9.14% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.21 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.46 |
| Sharpe Ratio 12m | -1.94 |
| Alpha | -41.69 |
| Beta | 0.911 |
| Volatility | 26.71% |
| Current Volume | 476.5k |
| Average Volume 20d | 332.1k |
| Stop Loss | 69.5 (-3.1%) |
| Signal | 0.00 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (104.8m TTM) > 0 and > 6% of Revenue (6% = 8.21m TTM) |
| FCFTA 0.21 (>2.0%) and ΔFCFTA 1.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 191.6% (prev 48.50%; Δ 143.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 129.3m > Net Income 104.8m (YES >=105%, WARN >=100%) |
| Net Debt (-124.8m) to EBITDA (137.4m) ratio: -0.91 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.69 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (51.5m) change vs 12m ago -0.33% (target <= -2.0% for YES) |
| Gross Margin -161.2% (prev 25.70%; Δ -186.9pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 20.80% (prev 76.16%; Δ -55.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.74 (EBITDA TTM 137.4m / Interest Expense TTM -38.6m) >= 6 (WARN >= 3) |
Altman Z'' 9.78
| (A) 0.46 = (Total Current Assets 416.8m - Total Current Liabilities 154.8m) / Total Assets 570.9m |
| (B) 1.15 = Retained Earnings (Balance) 658.8m / Total Assets 570.9m |
| warn (B) unusual magnitude: 1.15 — check mapping/units |
| (C) 0.16 = EBIT TTM 105.9m / Avg Total Assets 657.5m |
| (D) 1.83 = Book Value of Equity 656.5m / Total Liabilities 358.6m |
| Total Rating: 9.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.06
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.50% = 1.75 |
| 3. FCF Margin 88.42% = 7.50 |
| 4. Debt/Equity 0.21 = 2.48 |
| 5. Debt/Ebitda -0.91 = 2.50 |
| 6. ROIC - WACC (= 8.60)% = 10.75 |
| 7. RoE 24.77% = 2.06 |
| 8. Rev. Trend -47.19% = -3.54 |
| 9. EPS Trend 21.13% = 1.06 |
What is the price of EXPO shares?
Over the past week, the price has changed by +6.35%, over one month by +6.59%, over three months by +2.01% and over the past year by -24.70%.
Is Exponent a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EXPO is around 60.34 USD . This means that EXPO is currently overvalued and has a potential downside of -15.84%.
Is EXPO a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EXPO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 83 | 15.8% |
| Analysts Target Price | 83 | 15.8% |
| ValueRay Target Price | 67.8 | -5.5% |
EXPO Fundamental Data Overview November 02, 2025
P/E Trailing = 34.8818
P/E Forward = 31.5457
P/S = 6.8881
P/B = 8.0313
P/EG = 3.14
Beta = 0.911
Revenue TTM = 136.8m USD
EBIT TTM = 105.9m USD
EBITDA TTM = 137.4m USD
Long Term Debt = 81.5m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 6.49m USD (from shortTermDebt, last quarter)
Debt = 82.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.45b USD (3.58b + Debt 82.6m - CCE 207.4m)
Interest Coverage Ratio = -2.74 (Ebit TTM 105.9m / Interest Expense TTM -38.6m)
FCF Yield = 3.50% (FCF TTM 120.9m / Enterprise Value 3.45b)
FCF Margin = 88.42% (FCF TTM 120.9m / Revenue TTM 136.8m)
Net Margin = 76.65% (Net Income TTM 104.8m / Revenue TTM 136.8m)
Gross Margin = -161.2% ((Revenue TTM 136.8m - Cost of Revenue TTM 357.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 16.43%)
Tobins Q-Ratio = 6.04 (Enterprise Value 3.45b / Total Assets 570.9m)
Interest Expense / Debt = 7.77% (Interest Expense 6.42m / Debt 82.6m)
Taxrate = 27.38% (10.6m / 38.6m)
NOPAT = 76.9m (EBIT 105.9m * (1 - 27.38%))
Current Ratio = 2.69 (Total Current Assets 416.8m / Total Current Liabilities 154.8m)
Debt / Equity = 0.21 (Debt 82.6m / totalStockholderEquity, last quarter 402.9m)
Debt / EBITDA = -0.91 (Net Debt -124.8m / EBITDA 137.4m)
Debt / FCF = -1.03 (Net Debt -124.8m / FCF TTM 120.9m)
Total Stockholder Equity = 423.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.36% (Net Income 104.8m / Total Assets 570.9m)
RoE = 24.77% (Net Income TTM 104.8m / Total Stockholder Equity 423.3m)
RoCE = 20.98% (EBIT 105.9m / Capital Employed (Equity 423.3m + L.T.Debt 81.5m))
RoIC = 17.88% (NOPAT 76.9m / Invested Capital 430.1m)
WACC = 9.29% (E(3.58b)/V(3.66b) * Re(9.37%) + D(82.6m)/V(3.66b) * Rd(7.77%) * (1-Tc(0.27)))
Discount Rate = 9.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF Debug] Terminal Value 73.21% ; FCFE base≈130.3m ; Y1≈127.5m ; Y5≈129.6m
Fair Price DCF = 36.22 (DCF Value 1.83b / Shares Outstanding 50.5m; 5y FCF grow -3.13% → 3.0% )
EPS Correlation: 21.13 | EPS CAGR: 6.26% | SUE: -0.20 | # QB: 0
Revenue Correlation: -47.19 | Revenue CAGR: -71.43% | SUE: -4.0 | # QB: 0
Additional Sources for EXPO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle